Agreed. Most on here believe that a buyout is a matter of if not when, and most likely 50-100% over the SP at the time of buyout, at the least. Unless there is a better near term prospect, why would averaging up be bad? Proven well run company, exciting solid IP and drug, company that overall has found capital without causing significant SP drop(really, only this one since IPO). Yes, most has gone to instos, but how AT has operated, this isn't new.
we should have results of first cohort of multi dose in~3-4 months, which would put us around july. Coupled with sabre top line readouts, hopefully another inflection point for holders. There is a steady return of news in the next yr or two, which has a high chance of being positive.
Agreed. Most on here believe that a buyout is a matter of if not...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.80 |
Change
0.240(9.38%) |
Mkt cap ! $870.1M | |||
| Open | High | Low | Value | Volume |
| $2.86 | $2.90 | $2.66 | $5.887M | 2.115M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 116 | $2.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.85 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.80 |
Change
0.240 ( 9.77 %) |
||||
| Open | High | Low | Volume | ||
| $2.75 | $2.89 | $2.66 | 222147 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| CU6 (ASX) Chart |